First human test of 'Cancer Spotlight' imaging drug begins
NCT ID NCT07140315
Summary
This is a first-in-human study to test the safety of a new imaging drug called [18F]DK222. The drug is designed to stick to a specific protein (PD-L1) on cancer cells, potentially making tumors show up more clearly on a PET/CT scan. The trial will enroll 6 adults with lung or bladder cancer who are eligible for immunotherapy, to see how the drug moves through the body and if it is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.